Rocha-de-Lossada, CarlosLinero, Carmen AlbaOrtega, Álvaro SantosCalvo-de-Mora, Marina RodríguezRachwani, RahulBorroni, DavideAlba, EmilioOrgaz, Manuel BenavidesRomano, Vito2023-05-032023-05-032021-09-10http://hdl.handle.net/10668/21667The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.enAntibodies, Monoclonal, HumanizedHumansImmunoconjugatesVision Disordersresearch article3458624010.5935/0004-2749.202200391678-2925